MULTICENTER EVALUATION OF A NEW COMMERCIAL ASSAY FOR DETECTION OF IMMUNOGLOBULIN-M ANTIBODIES TO TOXOPLASMA-GONDII

A new commercial assay for detection of IgM-specific antibodies to Toxoplasma gondii (IMx Toro IgM, Abbott, USA), based on microparticle enzyme immunoassay technology, was evaluated at 15 clinical sites in Europe and the USA. Performance characteristics were established by testing clinical specimens collected randomly from pregnant women, blood donors, individuals with suspected Toxoplasma gondii infection and individuals confirmed HIV positive. Reference testing was performed using Toxo-M EIA (Abbott). Specimens evaluated at European sites yielding discordant results between the new assay and the reference EIA were further tested with an immunosorbent agglutination assay; at sites in the USA, discordant results were resolved using Platelia Toro IgM (Sanofi, France) and Vidas Toro IgM (bioMerieux, France) assays. In addition, matched plasma and serum, heat-treated and non-heat-treated specimens, and fresh and frozen specimens were evaluated at the USA sites. At European sites the new commercial assay had a sensitivity of 95.6% (196/205), a specificity of 99.8% (3,137/3,143) and an agreement of 99.6% (3,333/3,348) following resolution of discordant results; sensitivity in the USA was 97.4% (184/189), specificity was 99.8% (1,204/1,207) and agreement was 99.4% (1,388/1,396) following resolution. The new IMx Toro IgM is a sensitive and specific assay for measurement of IgM antibodies to Toxoplasma gondii in human serum and plasma.